2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1209

Sporadic Hemophagocytic Lymphohistiocytosis (sHLH): A Polygenic Disease? a Report of French National, Prospective, Cohort of 205 Patients
Abstract Number: 3019

Sputum Antibodies to Individual Citrullinated Protein/Peptide Antigens Are Elevated in Subjects at-Risk of Future RA and Subjects with Established Disease
Abstract Number: 2560

Sputum Antibody to Malondialdehyde-Acetaldehyde Adduct in Subjects with Established Rheumatoid Arthritis
Abstract Number: 2901

SSc and the Significance of Blood Group Antigens
Abstract Number: 1229

Stakeholder Needs Assessment for a New Model of Care for Pediatric Rheumatology in Ontario
Abstract Number: 1826

STAT3 Phosphorylation Mediates the Stimulatory Effects of Interferon Alpha on B Cell Differentiation and Activation in SLE
Abstract Number: 2178

Statin Use and Increased Risk of Musculoskeletal Conditions: A Retrospective Cohort Study with Propensity Score-Matching
Abstract Number: 1017

Statistical Simulation Using Data from the Foundation for the National Institute of Health/Osteoarthritis Initiative Biomarkers Consortium to Evaluate the Clinical Utility of Prognostic Knee Osteoarthritis Biomarkers in Designing a Knee Osteoarthritis Clinical Trial
Abstract Number: 671

Steered Screening for Sjögren Syndrome in Patients with Sicca Syndrome. Role of Salival Beta-2 Microglogulin
Abstract Number: 1347

Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis: Characteristics, Treatment and Outcome in 251 Cases from the Literature
Abstract Number: 630

Strategies for Biological Drug Quantification in Biological Drug Immune Responses
Abstract Number: 1040

Stressful Life Events : A Trigger for Rheumatoid Arthritis Onset within a Year. a Case-Control Study
Abstract Number: 2572

Study of Two Biomarkers of Biological Age in the Blood of Patients with Rheumatoid Arthritis
Abstract Number: 1835

Study on the Expression of NOD2 in Lupus Nephritis and Its Potential Signaling Pathway
Abstract Number: 684

Subchondral Bone Sclerosis on Computed Tomography – Does It Have Any Value in the Diagnosis of Inflammatory Sacroiliitis or Is It a Non-Specific Finding?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].